# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Illumina acquires Fluent BioSciences to enhance single-cell analysis and multiomics research. 10x Genomics faces challenges as ...
Illumina has acquired Fluent BioSciences, enhancing its single-cell analysis and multiomics capabilities. Fluent's innovati...
Stephens & Co. analyst Mason Carrico reiterates Illumina (NASDAQ:ILMN) with a Overweight and maintains $170 price target.
Citigroup analyst Patrick Donnelly upgrades Illumina (NASDAQ:ILMN) from Neutral to Buy and announces $140 price target.